HAYWARD, Calif.--(BUSINESS WIRE)--Oct. 15, 2018--
Pulse Biosciences, Inc. (NASDAQ: PLSE), a novel medical therapy company
bringing to market its proprietary Nano-Pulse Stimulation™ platform,
announced today that the Compensation Committee of the company’s Board
of Directors granted non-qualified stock options covering an aggregate
of 20,750 shares of Pulse Biosciences common stock to four new
non-executive employees under the Pulse Biosciences 2017 Inducement
Equity Incentive Plan on October 15, 2018.
The 2017 Inducement Equity Incentive Plan is used exclusively to grant
equity awards to individuals who were not previously an employee or
non-employee director of Pulse Biosciences as an inducement material to
such individual's entering into employment with Pulse Biosciences in
accordance with Nasdaq Marketplace Rule 5635(c)(4).
The options have an exercise price of $11.00 per share, which is equal
to the closing price of Pulse Biosciences common stock on October 15,
2018. The 20,750 shares underlying the option grants will vest and
become exercisable as to 25% of the shares on the first anniversary of
the recipient’s start date, and will vest and become exercisable as to
the remaining 75% of the shares in 36 equal monthly installments
following the first anniversary of the recipient’s start date, subject
to the recipient’s continued employment with Pulse Biosciences on these
vesting dates. The options are subject to the terms and conditions of
the 2017 Inducement Equity Incentive Plan and the award agreements
entered into with each recipient.
About Pulse Biosciences
Pulse Biosciences is a novel medical therapy company bringing to market
its proprietary Nano-Pulse Stimulation™ (“NPS™”) platform. NPS is a
novel, precise, non-thermal, treatment technology delivering nanosecond
duration energy pulses that impact cells in treated tissue while sparing
surrounding acellular tissue. NPS’s unique mechanism of action disrupts
the functions of internal cell structures while maintaining the outer
cell membrane initiating a cascade of events within the cell that
results in regulated cell death. In pre-clinical studies, NPS has
demonstrated an ability to induce immunogenic cell death in cancer cell
lines. The novel characteristics of NPS’s unique mechanism of action has
the potential to significantly benefit patients for multiple medical
applications, including dermatology, the Company’s first planned
commercial application, with future potential in other disease states
where an enhanced immune response may be beneficial. More information is
available at www.pulsebiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005912/en/
Source: Pulse Biosciences, Inc.
Pulse Biosciences, Inc.
Vice President and Chief Financial Officer
Gitanjali Jain Ogawa, 646-378-2949